Cedara releases strong 2Q FY05 results after eMed acquisition

Cedara Software Corp. released second quarter FY05 sales and earnings ending December 31, which for the first time include results of direct sales to hospitals and imaging centers since the company acquired eMed technologies in mid-October.
   
Revenues increased 89 percent to $23 million, compared with $12.1 million in the second quarter of FY04. Net income for the quarter climbed 27 percent to $4.9 million, compared with $3.9 million in the year-ago quarter. Cedara said this included approximately $1.1 million of eMed acquisition related charges.
   
For the six month period, revenues were $35.3 million, up 59 percent form the $22.3 million in the first half of FY04. Net income reached $8.1 million, compared with $5.6 million in the year-ago period.
   
According to Cedara, the strong growth in revenue for the quarter included a 75 percent increase in software license revenue to $12.5 million. Sales of systems and workstations (which include bundled software and hardware) reached $5.3 million. Support services revenue increased 42 percent to $3 million, while engineering services revenue declined slightly to $2.2 million.
   
In January, RIS/PACS vendor Merge eFilm and Cedara announced a definitive agreement to merge in an all-stock transaction. The companies said the merged entity could produce combined revenue of $100 million.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup